Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
S. Korea not to attend Sado mine memorial: foreign ministry
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
[THE INVESTOR] With Innotox, a liquid version of Botox, entering the third phase of clinical trials, analysts maintained “buy” ratings for the biopharmaceutical company, forecasting better performance in the second quarter.
As Allergan, a global leader that created Botox announced Aug. 9 that it will proceed to the next phase of trials for the injectable version of Botolinium toxin, developed and transferred by Medytox, “it is time to reevaluate it,” said Lee Seung-ho, an analyst at NH Investment & Securities.
As Allergan, a global leader that created Botox announced Aug. 9 that it will proceed to the next phase of trials for the injectable version of Botolinium toxin, developed and transferred by Medytox, “it is time to reevaluate it,” said Lee Seung-ho, an analyst at NH Investment & Securities.
The brokerage firm estimated the licensing to be worth 1.53 trillion won (US$1.40 billion), adding that the company also showed its strongest performance ever in the second quarter.
Eugene Investment’s Kwak Jin-hee agreed with the “buy” rating following the validation. “The value of Innotox, estimated to be worth 991 billion won, will gradually be reflected on that of the company. And the world market for Botolinium toxin and filler, another strength of Medytox, will show double digit growth by 2020,” she added.
By Hwang You-mee (glamazon@heraldcorp.com)
